Ultrafabrics Reports 3.6% Sales Decline, Operating Profit Drops 21.1%

Ultragenyx Pharmaceutical, Inc. has reported strong financial results for 2024, with total revenue reaching $560 million, marking a 29% year-over-year increase, driven primarily by its products Crysvita and Dojolvi. Despite this revenue growth, the company incurred a net loss of $569 million, although this was an improvement from the previous year's loss. For 2025, Ultragenyx projects revenue between $640 million and $670 million, continuing its focus on upcoming commercial launches and Phase 3 clinical trials. The company aims to manage expenses while advancing its therapeutic pipeline, which includes key programs for rare genetic diseases. In its latest quarterly report, Ultragenyx's performance was slightly below earnings expectations, but it did surpass revenue estimates. Analysts are closely monitoring the company's future earnings outlook and strategic direction as it seeks to achieve profitability.